<div id="readability-page-1"><div><p>Sept 25 (Reuters) - Intellia Therapeutics Inc:</p><ul><li>Intellia Therapeutics announces positive longer-term phase 1 data for nexiguran ziclumeran (Nex-Z) in patients with hereditary transthyretin (ATTR) amyloidosis with polyneuropathy</li><li>   Intellia Therapeutics Inc - one dose of Nex-Z shows durable TTR reductions of at least 90% through three years</li><li>   Intellia Therapeutics Inc - favorable safety data with no new drug-related events</li><li>   Intellia Therapeutics Inc - phase 3 Magnitude-2 trial enrollment expected by first half 2026</li></ul></div></div>

Intellia治疗

<p>9 月 25 日（路透社）- Intellia Therapeutics Inc：Intellia Therapeutics 宣布在遗传性转甲状腺素（ATTR）淀粉样变性伴多发性神经病患者中，nexiguran ziclumeran（Nex-Z）的长期 1 期研究数据积极。Intellia Therapeutics Inc - 一剂 Nex-Z 显示在三年内 TTR 减少至少 90% 的持久效果。Intellia Therapeutics Inc - 安全性数据良好，没有新的药物相关事件。Intellia Therapeutics Inc - 预计在 2026 年上半年开始进行 3 期 Magnitude-2 试验的招募</p>

Intellia 治疗公司称，Nex-Z 单剂在三年内可持续降低 TTR 至少 90%